Investigators who are writing grant applications and need a description of the Antibody Technology shared resource can find options below. Descriptions of the overall Fred Hutchinson Cancer Center Shared Resources program are available on the main Shared Resources grant information page.
Publications by Antibody Technology staff and grant awards to the core are listed below.
All publications, press releases, or other documents that cite results from CCSG-supported research must include acknowledgement of the grant and maintain compliance with NIH Public Access Policy. All manuscripts accepted for publication must be submitted to PubMed Central and be assigned a PMCID. Additionally, please reference the Research Resource Identifier (RRID). RRIDs are assigned to cores to help researchers cite key resources in the biomedical literature to improve transparency of research methods.
“This research was supported by the Antibody Technology Shared Resource, RRID:SCR_022608, of the Fred Hutch/University of Washington/Seattle Children’s Cancer Consortium (P30 CA015704).”
The Antibody Technology shared resource provides research teams with custom-designed monoclonal antibodies. Development activities focus on several areas: a) design of antigens, immunization and screening strategies, b) hybridoma cell line production via traditional methods, c) optimization of existing hybridoma cell lines by selection cloning and d) cloning, expression and engineering antibody variable regions.
The Antibody Technology shared resource is staffed by a multidisciplinary team of cell biologists with over 60 years of combined academic and industrial research experience. The team consists of the shared resource director and three scientific staff who work closely with several academic and industrial clients on a broad range of novel antibody discovery campaigns. Over the past eight years, the core has designed and operated a state-of-the-art antibody discovery platform and gained international recognition as a leader in the field. The team runs approximately 40 discovery campaigns annually with a successful portfolio of novel antibody compositions for therapeutic and diagnostic applications. The lab occupies 1,850 square feet in the Fred Hutch Eastlake Building and has been recently updated with over $2.5 million in new instrumentation. (Instrumentation: Tecan EVO, AATI Infinity, Molecular Devices ClonePix 2, IntelliCyt iQue Screener PLUS, Agilent Bravo, ÄKTA Pure, ProteinSimple WES, Carterra LSA). The team devises screening strategies for research teams using a novel bead/cell-based flow cytometric platform instead of traditional ELISA techniques, which significantly broadens the target scope. Monoclonal antibodies are screened against a multiplex of antigens allowing the simultaneous identification and/or counter-screening of antibodies to five unique targets or target analogs (purified proteins, carrier-coupled peptides and modified peptides). Having the shared resource on-site brings the overall development and production cost significantly below other academic and commercial fee-for-service labs. Since its inception in 1995, the core has developed over 7,500 monoclonal cell lines, several of which are commercially licensed.